Healthcare Industry News: Osiris Therapeutics
News Release - March 10, 2006
Blackstone Medical Plays Major Role in Spine Medicine Technology at First Stem Cell Summit in ChicagoSPRINGFIELD, Mass., March 10 (HSMN NewsFeed) -- Blackstone Medical Inc. brings breakthrough thinking to spine surgery technology at the first Stem Cell Summit in Chicago on March 21, 2006 sponsored by RRY Publications. Through a recent partnership with Osiris Therapeutics, Blackstone Medical, Inc. distributes Trinity, a surgery-ready, first-of-its-kind bone graft product containing viable adult stem cells. Trinity is unique in the field of biologics because it provides all three bone growth properties: osteoconductivity, osteoinductivity and osteogenesis and is free of donor matching or recipient immune expression concerns. It is also a safe alternative to autograft harvesting because it eliminates patient discomfort and the risk of inherent complication as well as reducing procedure time.
Key speakers at the Stem Cell Summit and at Blackstone's exclusive Tech Suite at AAOS this year are president of Blackstone Medical, Matthew Lyons, and board-certified orthopedic and spine surgery doctors Raymond J. Linovitz, MD, and Mark A. Lorenz, MD. Dr. Linovitz is the head of Blackstone's Research and Education program. Both doctors are members of Blackstone's Medical Advisory Board and have been vital in the development of several of Blackstone's principal spine devices.
Blackstone Medical, Inc., established in 1996, is a leading international spine product company dedicated to advancing techniques and technologies in the treatment of the human spine. Partnering with luminary spine surgeons to identify solutions and using a quality team approach with engineers, Blackstone creates breakthrough spinal implant and instrument products. Blackstone's achievement-driven focus results in rapid design, cooperative manufacturing and exceptional service to surgeons.
Osiris Therapeutics, Inc., founded in 1992, is the leader in adult stem cell therapy. This therapy can be used in patients unrelated to the donor, without rejection, eliminating the need for donor matching and recipient immune suppression. Once transplanted, the cells promote healing of damaged or diseased tissues. The Company's current focus includes the use of adult stem cells to improve outcomes in bone marrow recipients being treated for leukemia, to repair cardiac damage following a heart attack or congestive heart failure, and to present and treat orthopedic disorders. Osiris has leveraged this core expertise to create Trinity, a human cellular and tissue-based product for the repair, replacement or reconstruction of skeletal defects.
About Raymond J. Linovitz, MD, FACS
Fellowship trained in spinal disorders and actively involved in the development of new technology and surgical instruments for the spine, Dr. Linovitz is a board-certified orthopedic surgeon with more than 25 years in spine surgery and spinal disorders. Dr. Linovitz is the Medical Director of Research and Education for Blackstone Medical, Inc., the Medical Director of CORE Orthopedics Medical Center on the campus of Scripps Memorial Hospital in Encinitas, CA, and is a Principal Investigator for multiple IDEs. He limits his practice exclusively to treating problems of the spine.
About Mark A. Lorenz, MD
One of the first spine surgeons to be certified in artificial disc replacement, Dr. Lorenz is a board-certified, fellowship trained orthopedic surgeon specializing in spinal surgery at Hinsdale Orthopedic in Hinsdale, IL. A published writer of numerous articles in professional journals and orthopedic textbooks, Dr. Lorenz is an active researcher and educator and a frequent guest speaker at universities both in the U.S. and abroad.
Source: Blackstone Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.